These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 27765938)

  • 1. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway.
    Wu C; Luo J
    Med Sci Monit; 2016 Oct; 22():3860-3867. PubMed ID: 27765938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a].
    Li XN; Liu AH; Tang X; Ren Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):295-302. PubMed ID: 28416841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomes mediated transfer of lncRNA UCA1 results in increased tamoxifen resistance in breast cancer cells.
    Xu CG; Yang MF; Ren YQ; Wu CH; Wang LQ
    Eur Rev Med Pharmacol Sci; 2016 Oct; 20(20):4362-4368. PubMed ID: 27831634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.
    Li Z; Yu D; Li H; Lv Y; Li S
    Int J Oncol; 2019 Mar; 54(3):1033-1042. PubMed ID: 30628639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
    Lu PW; Li L; Wang F; Gu YT
    J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway.
    Liu H; Wang G; Yang L; Qu J; Yang Z; Zhou X
    PLoS One; 2016; 11(12):e0168406. PubMed ID: 27977766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
    Li X; Wu Y; Liu A; Tang X
    Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
    Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
    PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long Non-Coding RNA (lncRNA) 91H Confers Tamoxifen Resistance in ER+ Breast Cancer Cells through Inhibiting mTOR Signaling Pathway.
    Lv ZY; Mo QP; Tang HC; Zheng SS
    Ann Clin Lab Sci; 2022 Nov; 52(6):947-955. PubMed ID: 36564063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9.
    Jiang M; Huang O; Zhang X; Xie Z; Shen A; Liu H; Geng M; Shen K
    Molecules; 2013 Jan; 18(1):701-20. PubMed ID: 23299550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.
    Cheng N; Cai W; Ren S; Li X; Wang Q; Pan H; Zhao M; Li J; Zhang Y; Zhao C; Chen X; Fei K; Zhou C; Hirsch FR
    Oncotarget; 2015 Sep; 6(27):23582-93. PubMed ID: 26160838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway.
    Lu S; Du Y; Cui F; Feng X; Ma Y; Liu H
    Oncol Rep; 2019 Mar; 41(3):1901-1910. PubMed ID: 30747221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
    Xiong H; Jin X; You C
    Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of long noncoding RNA urothelial carcinoma associated 1 inhibits colorectal cancer cell proliferation and promotes apoptosis via modulating autophagy.
    Song F; Li L; Liang D; Zhuo Y; Wang X; Dai H
    J Cell Physiol; 2019 May; 234(5):7420-7434. PubMed ID: 30362538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adipocyte-conditioned medium induces tamoxifen resistance by activating PI3K/Akt/mTOR pathway in estrogen receptor-positive breast cancer cells.
    Nakatsuji M; Fujimori K
    Biochim Biophys Acta Mol Cell Res; 2024 Oct; 1871(7):119821. PubMed ID: 39159684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy.
    Wang J; Xie S; Yang J; Xiong H; Jia Y; Zhou Y; Chen Y; Ying X; Chen C; Ye C; Wang L; Zhou J
    J Hematol Oncol; 2019 Jul; 12(1):81. PubMed ID: 31340867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YBX1/lncRNA SBF2-AS1 interaction regulates proliferation and tamoxifen sensitivity via PI3K/AKT/MTOR signaling in breast cancer cells.
    Hussain SA; Venkatesh T
    Mol Biol Rep; 2023 Apr; 50(4):3413-3428. PubMed ID: 36754932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
    Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
    Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.